NCT02604823View on ClinicalTrials.gov

A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)

PHASE4CompletedINTERVENTIONAL

Enrollment

307

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Hepatitis B, Chronic

Interventions

DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.

Trial Locations (3)

100011

Beijing

200025

Shanghai

510630

Guangzhou

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02604823 - A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) | Biotech Hunter | Biotech Hunter